Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 16/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18694406 | 0.91 | CFTR (0.55) | CFTRKDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL18693870 | 0.87 | CFTR (0.60) | CFTRKDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL18693199 | 0.87 | CFTR (0.63) | CFTR | |
| SCHEMBL18693603 | 0.86 | CFTR (0.55) | CFTRKDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL18694697 | 0.86 | CFTR (0.62) | CFTRKDM4EHPGDHSD17B10 | |
| SCHEMBL18694521 | 0.86 | CFTR (0.74) | CFTRKDM4EHPGDHSD17B10 | |
| SCHEMBL18694519 | 0.84 | CFTR (0.58) | CFTRKDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL18694038 | 0.84 | CFTR (0.58) | CFTRKDM4EHPGDHSD17B10TDP1 | |
| SCHEMBL18692177 | 0.83 | CFTR (0.59) | CFTRKDM4EHPGDTDP1L3MBTL1 | |
| SCHEMBL18694195 | 0.83 | CFTR (0.58) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | claimed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | claimed |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | ABBVIE S.Á.R.L. (LU) | 2018-11-20 | — | — | US | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | ABBVIE S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | CFTR 1/4885KDM4E 4749/4885HPGD 1118/4885 |
| US-10130622-B2 | Compounds for treatment of cystic fibrosis | CFTR, CLCN2, SLC26A4 | CFTR 1/4885KDM4E 3964/4885HPGD 2415/4885 |
| US-20170100386-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, CLCN2, SLC26A4 | CFTR 1/4885KDM4E 3680/4885HPGD 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.